IPO

Filter News

Get news straight to your inbox by signing up for our free eNewsletters

Found 17,237 articles

  • Agile Therapeutics, Inc. today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,892,572 shares of common stock of the Company originally issued in July 2022 and May 2023, having an exercise price of $3.69 per share, at a reduced exercise price of $1.25 per share.

  • Zimmer Biomet Holdings, Inc. today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2024.

  • Madrigal Pharmaceuticals, Inc. today announced that the company granted equity awards to 46 new employees, in each case with a grant date of February 15, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan.

  • Modular Medical, Inc. announced the closing of its previously announced underwritten public offering of 9,090,910 shares of its common stock, led by Manchester Explorer, L.P., which is managed by Jeb Besser, Modular Medical's Chief Executive Officer, and Morgan Frank, a member of the Company's board of directors, and other existing institutional investors.

  • Chromocell Therapeutics Corporation (NYSE American: CHRO) (“Chromocell”, “our”, “us” or the “Company”), a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, today announced the closing of its initial public offering of 1,100,000 shares of its common stock at a public offering price of $6.00 per share.

  • Poolbeg Pharma announces that it has received notification that on 19 February 2024, Cathal Friel, Executive Chairman of the Company, purchased 830,000 ordinary shares at a price of 11.68 pence per share.

  • Chromocell Therapeutics Corporation announced the pricing of its initial public offering of 1,100,000 shares of common stock at a public offering price of $6.00 per share.

  • Theseus Pharmaceuticals, Inc. today announced that Concentra Biosciences, LLC ("Concentra") through its wholly owned subsidiary, Concentra Merger Sub II, Inc. ("Merger Sub"), has successfully completed the previously announced tender offer to acquire all outstanding shares of Theseus common stock for a price per share of (i) $4.05 in cash.

  • Satellos Bioscience Inc. announced today that its common shares will commence trading on the Toronto Stock Exchange (“TSX”) as of the opening of trading tomorrow under the Company’s current trading symbol, “MSCL”.

  • Shuttle Pharmaceuticals Holdings, Inc. today announced its intent to commence a Rights Offering where it plans to raise up to $4.5 million through the distribution of subscription rights and the exercise thereof, which full rights will entitle existing SHPH stockholders to purchase from the Company units (the "Units"), with each Unit consisting of (i) one share of SHPH common stock.

  • BioXcel Therapeutics, Inc. today announced that it has terminated its proposed public offering of $60.0 million of shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, previously announced on February 8, 2024.

  • Sunshine Biopharma, Inc. today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $10.0 million, before deducting underwriting fees and other estimated offering expenses payable by the Company.

  • BIOLASE, Inc. today announced the pricing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock.

  • MyMD Pharmaceuticals, Inc.® announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares.

  • CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the closing of its previously announced public offering of 3,875,000 shares of its common stock at a public offering price of $2.00 per share, for gross proceeds of $7.75 million, before deducting underwriting discounts and offering expenses.

  • Ensysce Biosciences, Inc. today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,601,752 shares of common stock.

  • Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”) today announced the closing of its initial public offering of 1,000,000 shares of common stock at a public offering price of $7.00 per share.

  • Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced the closing of its previously announced initial public offering of 6,250,000 of its common stock at a price to the public of $15.00 per share.

  • Bayer, Moderna-Backed Metagenomi’s Stock Crashes 31% in Friday IPO Debut

    Shares of preclinical genetic medicines company Metagenomi tanked more than 30% on Friday afternoon in a disappointing debut for its initial public offering, bucking the trend of positive IPOs so far this year.

  • Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (Nasdaq: RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion.

Subscribe